Understand your prostate health with advanced biomarker testing.
Take a proactive approach to your prostate health with Swan Science's Men's Advanced Prostate Health Check. This specialist blood test combines traditional Prostate Specific Antigen (PSA) testing with three additional biomarkers to provide a more detailed assessment of prostate cancer risk.
Prostate health becomes increasingly important as men get older. Changes affecting the prostate may develop without noticeable symptoms, making it valuable to understand your individual risk factors and the options available for assessment.
A more detailed approach to prostate health
Unlike a conventional PSA-only blood test, this advanced assessment measures four biomarkers associated with prostate health:
- Total PSA (Prostate Specific Antigen): A protein produced by the prostate gland. Elevated levels can occur for several reasons, including benign prostate enlargement, inflammation and prostate cancer.
- Interleukin-8 (IL-8): A signalling protein involved in inflammation and immune responses.
- Monocyte Chemotactic Protein-1 (MCP-1): A protein involved in immune-cell recruitment and inflammatory processes.
- Epidermal Growth Factor (EGF): A protein involved in cell growth and tissue repair.
These measurements contribute to a calculated
Prostate Cancer Risk Score, designed to provide additional information for prostate cancer risk assessment.
If total PSA is elevated, Free PSA is measured as an additional reflex test, providing further information that may help with clinical assessment.
Who might consider this test?
This assessment may be of interest to men who:
- Want to understand more about prostate health and their individual risk factors.
- Have a family history of prostate cancer and wish to discuss appropriate testing.
- Are considering PSA testing and would like information about a more detailed biomarker assessment.
- Have previously undergone prostate testing and have been advised by a healthcare professional to consider further assessment.
Men with urinary symptoms, blood in the urine or other concerning symptoms should consult their GP rather than relying on private blood testing alone.
Simple clinic blood collection
The test requires a venous blood sample, collected by a trained healthcare professional at a participating clinic.
Your sample is sent to a specialist laboratory for analysis, with results typically available within
72 hours of laboratory receipt.
The results include your measured biomarkers and calculated risk score, which can support a discussion with your GP or another appropriately qualified healthcare professional.
Understand your results and next steps
The aim of this test is to provide additional information about prostate-related biomarkers and estimated risk, helping you make informed decisions about your health.
An elevated PSA or higher calculated risk score does not necessarily mean prostate cancer is present. Equally, a normal PSA or lower risk score does not guarantee its absence.
The most appropriate next steps depend on your age, symptoms, family history, individual risk factors and clinical findings. Further assessment may include repeat PSA testing, examination, MRI or specialist referral when clinically indicated.
Important information
This test is intended to support prostate cancer risk assessment. It is
not a diagnostic test for prostate cancer and cannot definitively confirm or exclude the condition.
The additional biomarker-based risk score is a newer approach, and its clinical performance and suitability for individual patients should be considered alongside the available validation evidence.
Routine PSA screening is not currently recommended as a national screening programme in the UK. The potential benefits and limitations of testing should be considered before proceeding.
Understand your health. Know what to do next.
